- PROFESSOR Medicine, Hematology and Medical Oncology
- PROFESSOR Pediatrics
American Board of Internal Medicine
MD, University of Buenos Aires
Residency, Internal Medicine
Center for Medical Education
Mount Sinai Hospital
As leader of the Bone Marrow Transplantation (BMT) service at Mount Sinai, Dr. Isola promotes clinical and translational research on bone marrow transplantation. He has developed several protocols including non-ablative conditioning for allogeneic transplantation, the use of immunomagnetic technology for stem cell selection in haplo-mismatched transplantation and a combination of these two approaches for unrelated transplantation in older adults. Under his leadership the Mount Sinai BMT service performed the first mismatched transplantation using non-ablative conditioning. It is also one of only a few in the country with a FDA-approved protocol for haplo-mismatched transplantation. This is particularly important for minority populations as it is exceedingly difficult to find matched unrelated donors for patients from minorities. Also under his leadership, Mount Sinai was one of the first centers in the country to offer volunteer, unrelated peripheral blood stem cell collections for allotransplantation under the auspices of the National Marrow Donor Program. Dr. Isola has also been at the forefront in developing computerized systems for data management, capabilities that are crucial for maintaining accreditation by many organizations.
Stratton Foundation Award for Hematology Research
American Society of Hematology Scholar Award
American Society of Hematology
Research Award, 3rd. Annual Research Day of the Department of Medicine
Mount Sinai Medical School
Pan American Health Office Fellowship Award
Pan American Health Organization, W.H.O.
Price & Waterhouse House Staff Award
Department of Internal Medicine, Center for Medical Education and Clinical Research
Honour Diploma (Summa cum Laude)
University of Buenos Aires Medical School
Isola L, Gordon J. Anemia in a line of transgenic mice carrying a mutant dihydrofolate-reductase gene. Dev Genet 1988; 9: 181-191.
Isola L, Gordon J. Expression of a mutant dihydrofolate reductase gene in transgenic mice. Dev Genet 1989; 10: 349-355.
Bradbury M, Isola L, Gordon J. Enzymatic amplification of a repeated DNA sequence from the mouse Y chromosome allows identification of sex of preimplantation mouse embryos. Proc Natl Acad Sci U S A 1990; 87: 4053-4057.
Isola L, Zhou SL, Kiang C, Stump D, Berk P. Expression of a plasma membrane fatty acid binding protein and a saturable fatty acid uptake mechanism in 3T3 fibroblasts after transfection with a cDNA for mitochondrial glutamic - oxaloacetic transaminase. Proc Natl Acad Sci U S A 1995;.
Berk P, Zhou SL, Kiang CL, Stump D, Bradbury M, Isola L. Uptake of long chain free fattyacids is selectively upregulated in adipocytes of Zucker rats with genetic obesity and non insulin dependent diabetes mellitus. Journal of Biological Chemistry 1997; 272: 8830-8835.
Najfeld V, Burnett W, Vlachos A, Scigliano E, Isola L, Fruchtman S. Interphase FISH analysis of sex mismatched BMT utilizing dual color XY probes. Bone Marrow Transplant 1997; 19: 829-834.
Scaradavou A, Isola L, Rubinstein P, Galperin Y, Najfeld V, Berlin D, Gordon J, Weinberg R. A murine model for human cord blood transplantation: Near-term fetal and neonatal peripheral blood cells can achieve long-term bone marrow engraftment in sublethally irradiated adult recipients. Blood 1997; 89: 1089-1099.
Asch J, Weinberg R, Galperin Y, Kiang L, Mueller L, Jolly D, Isola L. Retroviral gene transfer into cord blood stem/progenitor cells using purified vector stocks. Am J Hematol 1998; 57: 16-23.
Skerrett D, Rosina O, Gudozowaty O, Isola L, Scigliano E, Fruchtman S. Comparative Analysis of HLA-B*8101 by Serology, Isoelectric Focusing, and Sequence-Based Typing. Human Immunology 1999; 60: 168-170.
Isola L, Scigliano E, Fruchtman S. Long Term Followup After Allogeneic G-CSF Primed Bone Marrow Transplantation. Biol Blood Marrow Transplant 2000 ; 6: 428.
- A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
- Phase II Study of the Addition of Azacitidine (IND #87574, NSC #102816) to Reduced-Intensity Conditioning Allogeneic Transplantation for Myelodysplasia (MDS) and Older Patients with AML
- A Phase II Controlled Trial of a Single ProHema-CB unit (Ex Vivo CXCR4-Upregulated CD34+ Hematopoietic Progenitor Cells, Cord Blood) As Part of a Double Umbilical Cord Blood Transplant Following Myeloablative Conditioning For Patients Age 15-55 Years With Hematologic Malignancies
- Filgrastim-Mobilized Blood Stem Cells for Transplantation
- A Trial of Single Autologous Transplant with or without Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for Patients with Multiple Myeloma
- A multicenter safety study of unlicensed, investigational cryopreserved cord blood units (CBUs) manufactured by the National Cord Blood Program (NCBP) and provided for unrelated hematopoietic stem cell transplantation of pediatric and adult patients
- A Phase III , Double Blind, Randomized, Placebo Controlled, Multicenter Clinical Trial to Study the Safety, Tolerability, Efficacy and Immunogenicity of V212 in Recipients of Autologous Hematopoietic Cell Transplants (HCTs)
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Isola did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website at http://icahn.mssm.edu/about-us/services-and-resources/faculty-resources/handbooks-and-policies/faculty-handbook. Patients may wish to ask their physician about the activities they perform for companies.
Icahn Medical Institute Floor 3 Room 310
1425 Madison Avenue
New York, NY 10029
19 East 98th Street Room Suite 4F
New York, NY 10029
5 East 98th Street, 10th floor
New York, NY 10029
- Monday 9:00am - 1:00pm
- Tuesday 1:00pm - 5:00pm
- Wednesday 1:00pm - 5:00pm
- Friday 1:00pm - 5:00pm
- 1199 National Benefit Fund
- Aetna U.S. Healthcare
- Anthem Health
- Blue Choice
- Blue Shield Premier
- Blue Shield of New Jersey
- CHUBB Health
- CIGNA - Indemnity
- CIGNA Healthcare HMO
- Empire Blue Cross/Blue Shield
- GHI HMO Select, Inc.
- Group Health Insurance, Inc.
- Healthnet-Empire BCBS
- MediChoice, Inc.
- Medicare Assignment
- Mount Sinai Health Systems
- Oxford Health Plans
- Physicians Health Services
- Prem Preferred Care/Beechstreet
- Private Healthcare Systems (PHCS)
- United Healthcare
- Master Card
- American Express
- Personal Check
1470 Madison Avenue
New York, NY 10029